BioAtla will receive an initial $5 million for general operating and Phase 3 clinical trial expenses to advance Oz-V in 2L+ OPSCC with the remaining $35 million anticipated to close in Q1 2026.BioAtla ...
The term "creator capital markets" was coined in 2025, with Pump.fun investing heavily into its livestreamer ecosystem.
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈